A BILL FOR AN ACT

RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

1 SECTION 1. Section 329-14, Hawaii Revised Statutes, is 2 amended as follows: 3 1. By amending subsection (b) to read: 4 "(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, 5 and ethers, unless specifically excepted, whenever the existence 6 of these isomers, esters, ethers, and salts is possible within 7 8 the specific chemical designation: 9 Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-(1) phenethyl) -4-piperidinyl] -N-phenylacetamide); 10 11 Acetylmethadol; (2) 12 (3) Allylprodine; Alphacetylmethadol (except levo-alphacetylmethadol, 13 (4)14 levomethadyl acetate, or LAAM); Alphameprodine; 15 (5) 16 (6) Alphamethadol;

```
Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-
1
          (7)
               phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-
2
3
               2-phenylethyl)-4-(N-propanilido) piperidine);
               Alpha-methylthiofentanyl (N-[1-methyl-2-(2-
4
          (8)
               thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);
5
6
         (9)
               Benzethidine;
7
        (10)
              Betacetylmethadol;
              Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-
8
        (11)
9
               piperidinyl] -N-phenylpropanamide);
10
        (12)
              Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-
               phenethyl) -3-methyl-4-piperidinyl]-N-
11
12
              phenylpropanamide);
13
        (13)
              Betameprodine;
14
        (14)
              Betamethadol;
15
              Betaprodine;
        (15)
16
        (16)
               Clonitazene;
17
              Dextromoramide;
        (17)
18
        (18)
              Diampromide;
19
              Diethylthiambutene;
        (19)
20
        (20)
              Difenoxin;
21
        (21)
              Dimenoxadol;
```

```
1
        (22)
              Dimepheptanol;
2
        (23)
              Dimethylthiambutene;
3
        (24)
              Dioxaphetyl butyrate;
4
        (25)
              Dipipanone;
5
        (26)
              Ethylmethylthiambutene;
6
        (27)
              Etonitazene;
7
        (28)
              Etoxeridine;
8
        (29)
              Furethidine;
9
              Hydroxypethidine;
        (30)
10
        (31)
              Ketobemidone;
11
        (32)
              Levomoramide;
12
              Levophenacylmorphan;
        (33)
13
        (34)
              3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-
14
              piperidyl] -N-phenylpropanamide);
15
        (35)
              3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-
16
              4-piperidinyl]-N-phenylpropanamide);
17
        (36)
              Morpheridine;
18
              MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);
        (37)
19
              Noracymethadol;
        (38)
20
        (39)
              Norlevorphanol;
21
        (40)
              Normethadone;
```

```
1
        (41)
              Norpipanone;
2
              Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-
        (42)
              phenethyl) -4-piperidinyl] propanamide;
3
              PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine;
4
        (43)
5
        (44)
              Phenadoxone;
6
        (45)
              Phenampromide;
7
        (46)
              Phenomorphan;
              Phenoperidine;
8
        (47)
9
        (48)
              Piritramide;
10
              Proheptazine;
        (49)
11
        (50)
              Properidine;
12
              Propiram;
        (51)
13
              Racemoramide;
        (52)
              Thiofentanyl (N-phenyl-N-[1-(2-thienyl) ethyl-4-
14
        (53)
              piperidinyl] -propanamide);
15
              Tilidine;
16
        (54)
17
        (55)
              Trimeperidine;
18
        (56)
              N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
19
              (benzylfentanyl), its optical isomers, salts, and
20
              salts of isomers;
```

```
1
              N-[1-(2-thienyl)methyl-4-piperidyl]-N-
        (57)
2
              phenylpropanamide (thenylfentanyl), its optical
              isomers, salts, and salts of isomers;
3
4
        (58)
              N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,
              (acetyl fentanyl), its optical, positional, and
5
6
              geometric isomers, salts, and salts of isomers;
7
        (59)
              AH-7921 (3,4-dichloro-N-[(1- dimethylamino)
8
              cyclohexylmethyl]benzamide), its isomers, esters,
9
              ethers, salts, and salts of isomers, esters, and
10
              ethers;
11
        (60)
              N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide, its
12
              isomers, esters, ethers, salts, and salts of isomers,
13
              esters, and ethers (Other names: Butyryl fentanyl);
14
              N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-
        (61)
15
              yl]-N-phenylpropionamide, its isomers, esters, ethers,
16
              salts and salts of isomers, esters, and ethers (Other
17
              names: beta-hydroxythiofentanyl);
18
        (62)
              N-(1-phenthylpiperidin-4-y1)-N-phenylfuran-2-
19
              carboxamide, its isomers, esters, ethers, salts, and
20
              salts of isomer, esters, and ethers (other names:
21
              Furanyl fentanyl);
```

```
1
        (63)
              3,4-dicholoro-N-[2-(dimethylamino)cyclohexyl]-N-
              methylbenzamide, its isomers, esters, ethers, salts
2
              and salts of isomers, esters, and ethers (Other names:
3
              U-47700):
4
5
              4-fluoroisobutyryl fentanyl or para-fluoroisobutyryl
        (64)
               [fenranyl] fentanyl [N-(4-fluorophenyl)-N-(1-
6
7
              phenethylpiperidin-4-yl)isobutyramide];
              Acryl fentanyl or acryloylfentanyl [N-(1-
8
        (65)
9
              phenethylpiperidin-4-yl) -N-phenylacrylamide]; [and]
              Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-
10
        (66)
11
              phenethylpiperidin-4-yl)acetamide] [-];
12
        (67)
              Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
13
              phenylcyclopropanecarboxamide;
14
              Methoxyacetyl fentanyl (2-methoxy-N-(1-
        (68)
15
              phenethylpiperidin-4-yl) -N-phenylacetamide);
16
              Ortho-Fluorofentanyl (N-(2-fluorophenyl)-N-(1-
        (69)
17
              phenethylpiperidin-4-yl)propionamide); other name: 2-
18
              fluorofentanyl); and
19
        (70)
              Para-Fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-
20
              phenethylpiperidin-4-yl)butyramide)."
21
             By amending subsection (e) to read:
         2.
```

1	"(e) Depressants. Unless specifically excepted, the
2	schedule shall include any material, compound, mixture, or
3	preparation which contains any quantity of the substance:
4	(1) Mecloqualone; [ex]
5	(2) Methaqualone[-];
6	(3) Etizolam (including its optical, positional, and
7	geometric isomers, salts, and salts of isomers, where
8	possible); or
9	(4) Flualprazolam (including its optical, positional, and
10	geometric isomers, salts, and salts of isomers, where
11	possible)."
12	3. By amending subsection (g) to read:
13	"(g) Any of the following cannabinoids, their salts,
14	isomers, and salts of isomers, unless specifically excepted,
15	whenever the existence of these salts, isomers, and salts of
16	isomers is possible within the specific chemical designation:
17	(1) Tetrahydrocannabinols; meaning tetrahydrocannabinols
18	naturally contained in a plant of the genus Cannabis
19	(cannabis plant), as well as synthetic equivalents of
20	the substances contained in the plant, or in the
21	resinous extractives of Cannabis, sp. or synthetic

1		substances, derivatives, and their isomers with
2		similar chemical structure and pharmacological
3		activity to those substances contained in the plant,
4		such as the following: Delta 1 cis or trans
5		tetrahydrocannabinol, and their optical isomers; Delta
6		6 cis or trans tetrahydrocannabinol, and their optical
7		isomers; and Delta 3,4 cis or trans-
8		tetrahydrocannabinol, and its optical isomers (since
9		nomenclature of these substances is not
10		internationally standardized, compounds of these
11		structures, regardless of numerical designation of
12		atomic positions, are covered);
13	(2)	Naphthoylindoles; meaning any compound containing a 3-
14		(1-naphthoyl)indole structure with substitution at the
15		nitrogen atom of the indole ring by a alkyl,
16		haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl,
17		1-(N-methyl-2-piperidinyl)methyl or 2-(4-
18		morpholinyl)ethyl group, whether or not further
19		substituted in the indole ring to any extent and
20		whether or not substituted in the naphthyl ring to any
21		extent;

S.B. NO. 5186 S.D. 1

1	(3)	Naphthylmethylindoles; meaning any compound containing
2		a 1H-indol-3-yl-(1-naphthyl) methane structure with
3		substitution at the nitrogen atom of the indole ring
4		by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
5		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
6		2-(4-morpholinyl) ethyl group whether or not further
7		substituted in the indole ring to any extent and
8		whether or not substituted in the naphthyl ring to any
9		extent;
10	(4)	Naphthoylpyrroles; meaning any compound containing a
11		3-(1-naphthoyl)pyrrole structure with substitution at
12		the nitrogen atom of the pyrrole ring by a alkyl,
13		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
14		1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)
15		ethyl group whether or not further substituted in the
16		pyrrole ring to any extent, whether or not substituted
17		in the naphthyl ring to any extent;
18	(5)	Naphthylmethylindenes; meaning any compound containing
19		a naphthylideneindene structure with substitution at
20		the 3-position of the indene ring by a alkyl,

haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

21

S.B. NO. 5186 S.D. 1

1		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
2		ethyl group whether or not further substituted in the
3		indene ring to any extent, whether or not substituted
4		in the naphthyl ring to any extent;
5	(6)	Phenylacetylindoles; meaning any compound containing a
6		3-phenylacetylindole structure with substitution at
7		the nitrogen atom of the indole ring by a alkyl,
8		haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
9		1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl)
10		ethyl group whether or not further substituted in the
11		indole ring to any extent, whether or not substituted
12		in the phenyl ring to any extent;
13	(7)	Cyclohexylphenols; meaning any compound containing a
14		2-(3-hydroxycyclohexyl) phenol structure with
15		substitution at the 5-position of the phenolic ring by
16		a alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
17		cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or
18		2-(4-morpholinyl) ethyl group whether or not
19		substituted in the cyclohexyl ring to any extent;
20	(8)	Benzoylindoles; meaning any compound containing a 3-
21		(benzoyl) indole structure with substitution at the

```
1
              nitrogen atom of the indole ring by a alkyl,
2
              haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
3
              1-(N-methyl-2-piperidinyl) methyl, or 2-(4-
              morpholinyl) ethyl group whether or not further
4
5
              substituted in the indole ring to any extent and
              whether or not substituted in the phenyl ring to any
6
7
              extent;
8
         (9)
              2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)
9
              pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-
              naphthalenylmethanone (another trade name is WIN
10
11
              55,212-2);
12
              (6a, 10a) -9-(hydroxymethyl) -6, 6-dimethyl-3-(2-
        (10)
13
              methyloctan-2-yl)-6a,7,10,10a-
14
              tetrahydrobenzo[c]chromen-1-ol (Other trade names are:
              HU-210/HU-211);
15
16
              Tetramethylcyclopropanoylindoles; meaning any compound
        (11)
17
              containing a 3-tetramethylcyclopropanoylindole
              structure with substitution at the nitrogen atom of
18
19
              the indole ring by an alkyl, haloalkyl, cyanoalkyl,
20
              alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-
21
              methyl-2-piperidinyl) methyl, 2-(4-morpholinyl) ethyl,
```

```
1
              1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
2
              morpholinyl) methyl, or tetrahydropyranylmethyl group,
              whether or not further substituted in the indole ring
3
4
              to any extent and whether or not substituted in the
              tetramethylcyclopropyl ring to any extent;
5
6
              N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide,
        (12)
              its optical, positional, and geometric isomers, salts,
7
              and salts of isomers (Other names: APINACA, AKB48);
8
9
              Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its
        (13)
              optical, positional, and geometric isomers, salts, and
10
              salts of isomers (Other names: PB-22; QUPIC);
11
12
              Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-
        (14)
              carboxylate, its optical, positional, and geometric
13
              isomers, salts, and salts of isomers (Other names: 5-
14
15
              fluoro-PB-22; 5F-PB-22);
16
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-
        (15)
17
              fluorobenzyl)-1H-indazole-3-carboxamide, its optical,
              positional, and geometric isomers, salts, and salts of
18
19
              isomers (Other names: AB-FUBINACA);
              N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-
20
        (16)
              indazole-3-carboxamide, its optical, positional, and
21
```

```
geometric isomers, salts, and salts of isomers (Other
1
2
              names: ADB-PINACA);
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-
3
        (17)
4
              (cyclohexylmethyl) -1H-indazole-3-carboxamide, its
              optical, positional, and geometric isomers, salts, and
5
              salts of isomers (Other names: AB-CHMINACA);
6
7
        (18)
              N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-
              indazole-3-carboxamide, and geometric isomers, salts,
8
9
              and salts of isomers (Other names: AB-PINACA);
              [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-
10
        (19)
              yl) methanone, and geometric isomers, salts, and salts
11
              of isomers (Other names: THJ-2201);
12
              Methyl (1-(4-fluorobenzyl)-1 H-indazole-3-carbonyl)-L-
13
        (20)
              valinate, and geometric isomers, salts, and salts of
14
              isomers (Other names: FUB-AMB[+][+], Methyl 2-(1-(4-
15
16
              fluorobenzyl)-1H-indazole-3-carboxamido)-3-
              methylbutanoate, MMB-FUBINACA, AMB-FUBINACA);
17
18
        (21)
              (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-
              carboxamido) - 3-methylbutanoate, and geometric isomers,
19
20
              salts, and salts of isomers (Other names: 5-fluoro-
21
              AMB, 5-fluoro-AMP);
```



```
1
        (22)
              N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-
2
              indazole-3-carboxamide, and geometric isomers, salts,
              and salts of isomers (Other names: AKB48 N-(5-
3
4
              fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl
              analog, 5F-APINACA);
5
              N-adamantyl-1-fluoropentylindole-3-Carboxamide, and
6
        (23)
              geometric isomers, salts, and salts of isomers (Other
7
8
              names: STS-135, 5F-APICA; 5-fluoro-APICA);
9
              Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-
        (24)
10
              carboxylate, and geometric isomers, salts, and salts
              of isomers (Other names: NM2201);
11
12
              N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
        (25)
13
              (cyclohexylmethyl) -1H-indazole-3-carboxamide, and
14
              geometric isomers, salts, and salts of isomers (Other
15
              names: MAB-CHMINACA and ADB-CHMINACA);
16
              Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-
        (26)
17
              carboxamido] -3,3-dimethylbutanoate (Other names: 5F-
18
              ADB, 5-flouro-ADB, and 5F-MDMB-PINACA), its optical,
19
              positional, and geometric isomers, salts, and salts of
20
              isomers; and
```

```
1
              1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
        (27)
2
              carboxamide (CUMYL-4CN-BINACA), its optical,
              positional, and geometric isomers, salts, and salts of
3
4
              isomers; also known as SGT-78, 4-CN-CUMYL-BINACA;
              CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano CUMYL-
5
6
              BUTINACA."
         SECTION 2. Section 329-16, Hawaii Revised Statutes, is
7
8
    amended by amending subsection (f) to read as follows:
9
               Immediate precursor. Unless listed in another
         "(f)
10
    schedule, any material, compound, mixture, or preparation which
11
    contains any quantity of the following substances:
12
              Immediate precursor to amphetamine and
         (1)
13
              methamphetamine:
14
                   Phenylacetone, phenyl-2-propanone(P2P), benzyl
              (A)
15
                   methyl ketone, methyl benzyl ketone;
16
              Immediate precursors to phencyclidine (PCP):
         (2)
17
                   1-phenylcyclohexylamine; [and] or
              (A)
                   1-piperidinocyclohexanecarbonitrile(PCC); or
18
              (B)
19
              Immediate precursor to Fentanyl:
         (3)
20
                   4-anilino-N-phenethyl-4-piperidine (ANPP) [-]; or
              (A)
```

```
(B) N-phenyl-N-(piperidin-4-yl)propionamide
1
2
                   (norfentanyl)."
         SECTION 3. Section 329-20, Hawaii Revised Statutes, is
3
4
    amended as follows:
5
         1. By amending subsection (b) to read:
               Depressants. Any material, compound, mixture, or
6
         "(b)
7
    preparation which contains any quantity of the following
    substances, including its salts, isomers, esters, ethers, and
8
9
    salts of isomers, whenever the existence of these isomers,
    esters, ethers, and salts is possible within the specific
10
    chemical designation, that has a degree of danger or probable
11
    danger associated with a depressant effect on the central
12
    nervous system:
13
14
         (1)
              Alprazolam;
15
              Barbital;
         (2)
16
         (3)
              Bromazepam;
17
         (4)
              Butorphanol;
         (5)
              Camazepam;
18
19
         (6)
              Carisoprodol;
         (7)
20
              Chloral betaine;
21
         (8)
              Chloral hydrate;
```

```
1
         (9)
              Chlordiazepoxide;
2
        (10) Clobazam;
3
        (11)
              Clonazepam;
4
        (12) Clorazepate;
5
        (13) Clotiazepam;
6
        (14)
              Cloxazolam;
7
        (15)
              Delorazepam;
8
        (16)
              Dichloralphenazone (Midrin);
9
        (17)
              Diazepam;
10
        (18)
              Estazolam;
11
        (19)
              Ethchlorvynol;
12
        (20)
              Ethinamate;
13
        (21)
              Ethyl loflazepate;
14
        (22)
              Fludiazepam;
15
              Flunitrazepam;
        (23)
16
        (24)
              Flurazepam;
17
        (25)
              Fospropofol (Lusedra);
18
        (26)
              Halazepam;
19
        (27)
              Haloxazolam;
20
        (28)
              Ketazolam;
21
```

Loprazolam;

(29)

```
1
        (30)
              Lorazepam;
2
        (31)
              Lormetazepam;
3
        (32)
              Mebutamate;
4
        (33)
              Medazepam;
5
        (34)
              Meprobamate;
6
        (35)
              Methohexital;
7
        (36)
              Methylphenobarbital (mephorbarbital);
8
        (37)
              Midazolam;
9
        (38)
              Nimetazepam;
10
        (39)
              Nitrazepam;
11
        (40)
              Nordiazepam;
12
        (41)
              Oxazepam;
13
        (42)
              Oxazolam;
14
        (43)
              Paraldehyde;
15
        (44)
              Petrichloral;
16
              Phenobarbital;
        (45)
17
        (46)
              Pinazepam;
18
        (47)
              Prazepam;
19
        (48)
              Quazepam;
20
        (49)
              Suvorexant;
21
        (50)
              Temazepam;
```

```
1
        (51)
              Tetrazepam;
2
        (52)
              Triazolam;
3
        (53)
              Zaleplon;
4
              Zolpidem; [and]
        (54)
5
              Zopiclone (Lunesta) [-]; and
        (55)
        (56) Brexanolone."
6
7
         2. By amending subsection (d) to read:
               Stimulants. Unless listed in another schedule, any
8
9
    material, compound, mixture, or preparation which contains any
    quantity of the following substances having a stimulant effect
10
    on the central nervous system, including its salts, isomers, and
11
    salts of such isomers whenever the existence of such salts,
12
    isomers, and salts of isomers is possible within the specific
13
14
    chemical designation:
              Cathine ((+)-norpseudoephedrine);
15
         (1)
16
              Diethylpropion;
         (2)
17
         (3)
              Fencamfamin;
18
         (4)
              Fenproporex;
19
              Mazindol;
         (5)
20
         (6)
              Mefenorex;
21
         (7)
              Modafinil;
```

Phentermine: 1 (8) Pemoline (including organometallic complexes and 2 (9) 3 chelates thereof); 4 (10) Pipradrol; 5 (11) Sibutramine; SPA (1-dimethylamino-1,2-diphenylethane, lefetamine); 6 (12)7 [and] 8 (13)Lorcaserin[→]; and 9 Solriamfetol." (14)10 SECTION 4. Section 329-22, Hawaii Revised Statutes, is 11 amended to read as follows: 12 "§329-22 Schedule V. (a) The controlled substances 13 listed in this section are included in schedule V. (b) Narcotic drugs containing nonnarcotic active medicinal 14 ingredients. Any compound, mixture, or preparation containing 15 limited quantities of any of the following narcotic drugs, which 16 **17** also contains one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the 18 compound, mixture, or preparation, valuable medicinal qualities 19 20 other than those possessed by the narcotic drug alone:

S.B. NO. \$1186 S.D. 1

1	(1 /	Not more than 200 milligrams of codeline, or any or its
2		salts, per 100 milliliters or per 100 grams;
3	(2)	Not more than 100 milligrams of dihydrocodeine, or any
4		of its salts, per 100 milliliters or per 100 grams;
5	(3)	Not more than 100 milligrams of ethylmorphine, or any
6		of its salts, per 100 milliliters or per 100 grams;
7	(4)	Not more than 2.5 milligrams of diphenoxylate and not
8		less than 25 micrograms of atropine sulfate per dosage
9		unit;
10	(5)	Not more than 100 milligrams of opium per 100
11		milliliters or per 100 grams; and
12	(6)	Not more than 0.5 milligram of difenoxin and not less
13		than 25 micrograms of atropine sulfate per dosage
14		unit.
15	(c)	Stimulants. Unless specifically exempted or excluded
16	or unless	listed in another schedule, any material, compound,
17	mixture, o	or preparation that contains any quantity of the
18	following	substances having a stimulant effect on the central
19	nervous sy	ystem, including its salts, isomers, and salts of
20	isomers.	

```
Depressants. Unless specifically exempted or excluded
1
         (d)
    or unless listed in another schedule, any material, compound,
2
    mixture, or preparation that contains any quantity of the
3
    following substances having a depressant effect on the central
4
    nervous system, including its salts, isomers, and salts of
5
6
    isomers:
7
              Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-
         (1)
              propionamide], (Vimpat);
8
              Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic
9
         (2)
10
              acid]; and
11
              Brivaracetam ((2S)-2[(4R)-2-oxo-4-propylpyrrolidin-1-
         (3)
              yl]butanamide) (Other names: BRV; UCB-34714; Briviact)
12
13
              and its salts.
14
         [(e) Approved cannabidiol drugs. A drug product in
15
    finished dosage formulation that has been approved by the United
    States Food and Drug Administration that contains cannabidiol
16
    (2-[1R-3-methyl-6R-(1-methylethenyl)-2-cyclohexen-1-yl]-5-
17
    pentyl-1,3-benzenediol) derived from cannabis and no more than
18
19
    0.1 percent (w/w) residual tetrahydrocannabinols.]"
20
         SECTION 5. Statutory material to be repealed is bracketed
21
    and stricken. New statutory material is underscored.
```

1 SECTION 6. This Act shall take effect upon its approval.

Report Title:

Uniform Controlled Substances Act

Description:

Updates the Uniform Controlled Substances Act, chapter 329, Hawaii Revised Statutes, to make it consistent with amendments in the federal controlled substances law as required by section 329-11, Hawaii Revised Statutes. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.